BRP Recalling Thousands of Snowmobiles Due to Safety Risk
By Robb M. Stewart
The parent company of Ski-Doo is recalling thousands of snowmobiles in the U.S. and Canada because of the risk a ski could break and cause a crash and serious injury, the U.S. safety watchdog said.
The Consumer Product Safety Commission in a notice said the safety recall involves all of BRP's 2024 Ski-Doo MXZ and Renegade snowmobiles equipment with "Pilot X" skis. The recall covers about 8,100 of the snowmobiles in the U.S., and about 5,600 that were sold in Canada.
The commission said owners should immediately stop using the vehicles and contract BRP to schedule a free inspection and for a no-cost replacement of the left ski at a dealership.
The Canadian company in late January wrote to Ski-Doo owners advising them of the safety recall. It said the left Pilot X skis may break due to a molding process issue at the supplier.
While the fix should take less than an hour to complete, BRP said a limited number of parts were available in Canada and the U.S. In other countries, parts were set to be available from Feb. 8, it said.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
February 29, 2024 11:42 ET (16:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks